• Senti Biosciences Holdings divested Midco and operating subsidiary Senti Biosciences to ST NewCo, transferring substantially all its existing business and pipeline.
• The company retained its Rett Syndrome and TIL programs, supported by intellectual property and contracts transferred before closing.
• Merger consideration consists of contingent value rights worth up to $60 million, payable upon SENTI-202 milestones achieved within seven years.
• Pro forma estimates show a $6.65 million disposal loss, incorporating the expected exchange of $16 million of Notes at $0.342 per share.
• ST NewCo purchased $2.5 million of common stock at closing to fund continuing operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-040772), on October 26, 2026, and is solely responsible for the information contained therein.